Channelchek - Looking for the next apple? This is the orchard.

ZOMDF

$0.09

(1.13%)

FLWS

$4.04

(3.06%)

ACCO

$4.16

(4.79%)

ARLP

$24.71

(0.57%)

AUIAF

$0.15

(0%)

AZZ

$150.83

(0.25%)

BTBT

$1.48

(-6.34%)

BTM

$0.49

(0%)

CVKD

$2.42

(2.98%)

LCE:CA

$0.25

(0%)

COCP

$0.95

(-0.73%)

CDRO

$9.54

(-0.52%)

CVGI

$4.66

(-2.71%)

LODE

$3.92

(-5.77%)

CMTL

$1.67

(-4.86%)

CNDT

$1.57

(3.29%)

CXW

$30.73

(-1.14%)

CMLS

$0.01

(0%)

DRCT

$2.46

(-4.65%)

DLHC

$5.65

(5.02%)

SSP

$3.1

(0.49%)

ELDN

$3.81

(-5.1%)

EVC

$10.38

(-6.19%)

EDRY

$23.04

(0.2%)

ESEA

$72

(0.78%)

FAT

$0.16

(0%)

RAIL

$7.75

(-2.64%)

GDEV

$11.7

(0%)

GOVX

$0.86

(-14.84%)

GOCO

$0.3

(0%)

GHM

$107.92

(-2.07%)

GLDD

$17

(0%)

GYRE

$7.58

(-1.88%)

HMENF

$1.85

(-2.12%)

III

$4.08

(2.77%)

IPOOF

$10.46

(-1.88%)

KELYA

$15.43

(7.68%)

KTOS

$46.81

(-5.77%)

LUCK

$7.31

(1.67%)

MAIA

$1.35

(-8.16%)

MGROF

$0.26

(0%)

NTRB

$3.14

(2.95%)

OCGN

$1.35

(-5.24%)

PERF

$1.93

(0.26%)

QMCI

$0.15

(0%)

RGP

$4.82

(4.9%)

SGA

$9.25

(-0.13%)

SHWZ

(0%)

SHIP

$14.76

(-3.12%)

SLQT

$0.72

(-3.41%)

SKYX

$1.18

(-5.6%)

SNAL

$5.07

(2.01%)

GEO

$29.6

(-0.74%)

ODP

$28

(0%)

TNXP

$11.63

(0.17%)

TSQ

$6.72

(-0.88%)

TZOO

$11.03

(-0.45%)

UNCY

$5.02

(0%)

VVX

$75.04

(-0.81%)

VNCE

$6.27

(1.79%)

XELB

$1.42

(-4.05%)

ZOMDF

$0.09

(1.13%)

FLWS

$4.04

(3.06%)

channelchek-in

‌

7/16/2026

Eli Lilly Pays $3.8 Billion for AtaiBeckley as Big Pharma’s Push Into Mental Health Enters a New Phase

The pharmaceutical industry’s appetite for neuroscience innovation just produced one of the most significant mental health deals in years. Eli Lilly (NYSE: LLY) announced Wednesday it has entered into a definitive agreement to acquire AtaiBeckley (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing rapid-acting therapies for treatment-resistant depression and other serious mental health conditions. The deal values AtaiBeckley at approximately $2.8 billion in upfront equity consideration, with an additional $1.0 billion in potential milestone-based contingent value rights, bringing the total potential transaction value to approximately $3.8 billion.

3 min read